101.87
2.16%
2.15
Handel nachbörslich:
101.95
0.08
+0.08%
Schlusskurs vom Vortag:
$99.72
Offen:
$99.3
24-Stunden-Volumen:
1.17M
Relative Volume:
1.18
Marktkapitalisierung:
$24.42B
Einnahmen:
$3.30B
Nettoeinkommen (Verlust:
$-501.07M
KGV:
8.8288
EPS:
11.5384
Netto-Cashflow:
$1.03B
1W Leistung:
-6.31%
1M Leistung:
-8.86%
6M Leistung:
+12.43%
1J Leistung:
+2.50%
Biontech Se Adr Stock (BNTX) Company Profile
Vergleichen Sie BNTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
2024-05-14 | Eingeleitet | Evercore ISI | In-line |
2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
2024-01-05 | Eingeleitet | Oppenheimer | Perform |
2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
2023-07-14 | Eingeleitet | HSBC Securities | Buy |
2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
2022-08-17 | Eingeleitet | Cowen | Market Perform |
2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
2021-10-07 | Eingeleitet | Jefferies | Hold |
2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
2021-05-18 | Eingeleitet | Goldman | Neutral |
2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
2020-08-03 | Fortgesetzt | Berenberg | Buy |
2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2020-01-22 | Herabstufung | UBS | Buy → Neutral |
2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
2019-11-04 | Eingeleitet | Berenberg | Buy |
2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
2019-11-04 | Eingeleitet | JP Morgan | Overweight |
2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register
Powell Speaks The Truth - Benzinga
Goodwin, Conyers, A&O Shearman Act on $800M China Biotech Sale - Law.com International
BioNTech ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition - Benzinga
BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch
BioNTech SE ADR falls Monday, underperforms market - MarketWatch
BioNTech SE ADR rises Friday, outperforms market - MarketWatch
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
BioNTech SE Reports Strong Q3 2024 Results - TipRanks
This 6%-yielding U.S. pharma giant is a safe hold - The Globe and Mail
BioNTech SE ADR falls Friday, underperforms market - MarketWatch
BioNTech SE ADR outperforms market despite losses on the day - MarketWatch
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - Nasdaq
BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - MSN
BioNTech SE ADR rises Thursday, outperforms market - MarketWatch
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
BioNTech SE ADR rises Wednesday, still underperforms market - MarketWatch
A better buy-in window may exist right now for BioNTech SE ADR (BNTX) - SETE News
Insider’s View: Deciphering BioNTech SE ADR (BNTX)’s Financial Health Through Ratios - The Dwinnex
BioNTech SE ADR (BNTX)’s stock decline to 121.55 per share - US Post News
BioNTech SE ADR falls Monday, still outperforms market - MarketWatch
What is BioNTech SE ADR (BNTX) Stock Return on Shareholders’ Capital? - SETE News
BioNTech SE ADR (BNTX)’s results reveal risk - US Post News
Gaining Ground: BioNTech SE ADR (BNTX) Closes Higher at 119.93, Up 0.98 - The Dwinnex
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance
BioNTech unveils AI advancements in immunotherapy - Investing.com
BioNTech SE ADR rises Monday, outperforms market - MarketWatch
BioNTech SE ADR (BNTX) can make a big difference with a little luck - SETE News
Wall Street SWOT: BioNTech stock shows promise amid oncology pipeline growth - Investing.com
Are Smart Investors Making the Right Decision? BioNTech SE ADR (BNTX) - SETE News
What Are You Thinking About Investing In BioNTech SE ADR (NASDAQ: BNTX) Stock? - Stocks Register
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):